Success for First-Line PARP Inhibition in Ovarian Cancer.
The use of PARP inhibitors as first-line maintenance therapy for advanced ovarian cancer improves progression-free survival, according to three phase III studies. The data also suggest that patients other than those with BRCA1/2 mutations may benefit from this class of drugs.